News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Policy
CBER: Supplement Approval: Influenza Virus Vaccine (FluLaval)
July 28, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Product Approval Information - Licensing Action
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
MORE ON THIS TOPIC
Regulatory
Novo Nordisk Snags Kidney Disease Expansion for Ozempic in Europe
December 12, 2024
·
1 min read
·
Kate Goodwin
Government
Lilly, Pfizer Execs Sing Optimistic Tune on Incoming Admin After Trump Dinner
December 12, 2024
·
2 min read
·
Tristan Manalac
Legal
Former CytoDyn Officials Found Guilty of Securities Fraud
December 12, 2024
·
2 min read
·
Tristan Manalac
Neurodegenerative disease
UniQure Clears Path to Accelerated Approval for Huntington’s Gene Therapy
December 10, 2024
·
2 min read
·
Tristan Manalac
